Jumpcode Genomics Expands Team with Appointment of Three Executives
Welcomes Vice President of Research and Development, Vice President of Marketing and Vice President of Sales to fuel innovation and growth
SAN DIEGO, Calif. — Jumpcode Genomics, a genome technology platform company focused on enabling genomic analysis, today announced the appointment of three new key hires to its growing team. Jon Armstrong joins the company as Vice President of Research and Development, along with Kerri McWeeny as Vice President of Marketing and Jonathan Bell as Vice President of Sales.
“All three of our new hires have extensive experience in the genomics space and we’re excited to have them on board to help execute on our mission,” said Yaron Hakak, CEO of Jumpcode Genomics. “The combination of Jon’s scientific leadership plus product development experience, Kerri’s expertise in marketing for life science technology organizations and Jonathan’s sales experience for genomic solutions is a recipe for success as we look to accelerate our growth.”
Jon Armstrong joins Jumpcode Genomics as Vice President of Research and Development. Most recently, Jon served as Chief Scientific Officer for Cofactor Genomics, a predictive immune modeling company, which he cofounded. In this role, Jon led product launches for more than a dozen genomics solutions for the research and clinical space. Prior to Cofactor Genomics, Jon spent nearly a decade in Elaine Mardis’ lab at The Washington University Genome Institute, where he helped develop technologies in microarray, next-generation sequencing, molecular biology and cancer genetics.
Kerri McWeeny joins Jumpcode from Illumina, where she most recently served as a Senior Director in marketing. Kerri joined Illumina in 2012, holding leadership roles in global pricing strategy, marketing strategy and communications throughout her tenure. Prior to Illumina, she held commercial leadership roles at MO BIO Laboratories and GenVault Corp, as well as research and development roles at Motorola Life Sciences and Abbott Laboratories.
Jonathan Bell joins Jumpcode with deep commercial experience in driving the growth of disruptive genomic technologies. He has held positions with progressively increasing responsibilities in the areas of sales, product marketing and regional marketing for life sciences companies, including Affymetrix, Illumina and 10x Genomics. Jonathan most recently served as a Vice President for Celsee (acquired by Bio-Rad).
About Jumpcode Genomics
Jumpcode Genomics is changing the way scientists see their samples with our proprietary CRISPRclean® technology. Combining CRISPR-based technology and next-generation sequencing (NGS) they can now search for and find novel signals they previously couldn’t. Our technology removes unwanted sequences, allowing researchers worldwide to extract greater insights. By increasing sensitivity and allowing access to a range of sample types, we’re broadening the understanding of human biology in fields from research to clinical applications including infectious disease and oncology. Discover what we can do.